{"product_id":"cjc-1295-no-dac","title":"CJC-1295 (No DAC)","description":"\u003cdiv class=\"prod-section\"\u003e \u003cdiv class=\"prod-section-label\"\u003e \u003ci class=\"ti ti-file-description\"\u003e\u003c\/i\u003eResearch Background \u003c\/div\u003e \u003cp class=\"prod-para\"\u003e CJC-1295 (No DAC) is a modified GRF(1-29), a 29-amino acid GHRH analog with four amino acid substitutions that enhance alpha-helical structure and confer 49x greater receptor potency versus native GHRH. The No DAC version features a shorter in vivo half-life (~30 minutes) designed for discrete pulsatile GH signal research, allowing researchers to study physiological growth hormone release patterns without the extended release profile of the DAC-modified version. \u003c\/p\u003e \u003cp class=\"prod-para\"\u003e CJC-1295 functions as a potent GHRH receptor agonist, binding to and activating growth hormone-releasing hormone receptors on pituitary somatotroph cells. The four amino acid substitutions (Aib, Gln, Ala, and Leu at positions 2, 8, 15, and 27) protect against enzymatic degradation while maintaining receptor binding affinity. This structural modification results in significantly enhanced stability and bioavailability compared to unmodified GRF(1-29). \u003c\/p\u003e \u003cp class=\"prod-para\"\u003e In research applications, CJC-1295 (No DAC) stimulates pulsatile growth hormone release, leading to increased IGF-1 production in hepatic and peripheral tissues. The absence of the Drug Affinity Complex (DAC) means the peptide does not bind to albumin for extended circulation, resulting in a more physiological release pattern that mimics natural GH pulsatility. This makes it particularly valuable for research protocols requiring precise temporal control over GH signaling. \u003c\/p\u003e \u003cp class=\"prod-para\"\u003e The peptide demonstrates remarkable efficacy in stimulating GH release without significantly affecting cortisol, prolactin, or other stress hormone levels when used appropriately. This selectivity makes it a preferred research tool for studying GH axis function, anabolic processes, metabolic regulation, and age-related endocrine changes without confounding effects from other hormonal systems. \u003c\/p\u003e \u003c\/div\u003e \u003cdiv class=\"prod-section\"\u003e \u003cdiv class=\"prod-section-label\"\u003e \u003ci class=\"ti ti-atom\"\u003e\u003c\/i\u003ePhysicochemical Data \u003c\/div\u003e \u003cdiv class=\"table-scroll\"\u003e \u003ctable class=\"prod-table\"\u003e \u003cthead\u003e \u003ctr\u003e \u003cth\u003eCompound\u003c\/th\u003e \u003cth\u003eMW \/ Formula\u003c\/th\u003e \u003cth\u003eCAS No.\u003c\/th\u003e \u003cth\u003eSequence \/ Structure\u003c\/th\u003e \u003cth\u003eReceptor \/ Target\u003c\/th\u003e \u003c\/tr\u003e \u003c\/thead\u003e \u003ctbody\u003e \u003ctr class=\"row-alt\"\u003e \u003ctd class=\"td-bold\"\u003eCJC-1295 (No DAC)\u003c\/td\u003e \u003ctd\u003e~3367 g\/mol\u003c\/td\u003e \u003ctd\u003e863288-34-0\u003c\/td\u003e \u003ctd\u003e29-AA GHRH fragment; 4× substitutions; 49× native GHRH potency\u003c\/td\u003e \u003ctd\u003eModified GRF(1-29); GHRH receptor agonist\u003c\/td\u003e \u003c\/tr\u003e \u003c\/tbody\u003e \u003c\/table\u003e \u003c\/div\u003e \u003c\/div\u003e","brand":"General Peptide","offers":[{"title":"1 Vial","offer_id":50856778137847,"sku":null,"price":47.0,"currency_code":"USD","in_stock":true},{"title":"3 Vials","offer_id":50856778170615,"sku":null,"price":127.0,"currency_code":"USD","in_stock":true},{"title":"5 Vials","offer_id":50856778203383,"sku":null,"price":188.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0934\/1485\/0807\/files\/Endocrine-GH_CJC-1295-_No-DAC.jpg?v=1781176582","url":"https:\/\/generalpeptide.com\/products\/cjc-1295-no-dac","provider":"General Peptide","version":"1.0","type":"link"}